ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control Recruiting nowThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
Immunotherapy duo shows promise against returning uterine cancer
Disease control Recruiting nowThis study compares two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone in people with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). The goal is to see if the combination shrinks tumors better. About 81 participants will receive…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New hope for endometrial cancer: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called ACR-368, given alone or with a very low dose of chemotherapy, in people with advanced endometrial cancer. The goal is to see if the drug can shrink tumors. About 400 participants will join this phase 2 trial to check both safety and ef…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Jun 01, 2026 17:57 UTC